The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Open accessAbstract
Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence. Patients and Methods: From January 1980 to August 2012, 4,774 patients who underwent primary treatment and estrogen (ER) and progesterone receptor (PgR) assessment were enrolled in this study. The patients were divided into two groups, those with a follow-up period <10 years and those without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients followed up for <10 years and in 51 patients for ≥10 years. Results: The overall 10-year cumulative disease-free survival rate was 79.5%, and the recurrence rate at ≥10 years was 5.8%. A multivariate analysis revealed that the factors related to late recurrence were PgR positivity and positive nodes. This result differed from that for early recurrence in terms of ER/PgR, Ki-67 index and p53 overexpression. Conclusion: PgR positivity and lymph node metastases significantly correlated with late recurrence. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Research works printed but not linked: 3
- 10.1007/s10147-006-0601-6 · doi:10.1007/s10147-006-0601-6
- 10.1186/1477-7819-9-131 · doi:10.1186/1477-7819-9-131
- 10.1186/bcr2143 · doi:10.1186/bcr2143
Cited by
Items 501–600 of 787
Koch, A., Jeschke, J., Van Criekinge, W., van Engeland, M., & De Meyer, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz445 · Cited by 306
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
Ali, H. R., Jackson, H. W., Zanotelli, V. R. T., Danenberg, E., Fischer, J. R., Bardwell, H., Provenzano, E., CRUK IMAXT Grand Challenge Team, Ali, H. R., Al Sa’d, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0026-6 · Cited by 306
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., Beaty, K. A., Dehan, E., & Parikh, B. (2019) · Human Genetics · doi:10.1007/s00439-019-01970-5 · Cited by 305
PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis
Liu, F., Ma, F., Wang, Y., Hao, L., Zeng, H., Jia, C., Wang, Y., Liu, P., Ong, I. M., Li, B., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3630 · Cited by 305
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
–Omic and Electronic Health Record Big Data Analytics for Precision Medicine
Wu, P.-Y., Cheng, C.-W., Kaddi, C. D., Venugopalan, J., Hoffman, R., & Wang, M. D. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2573285 · Cited by 303
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Choi, W., Czerniak, B., Ochoa, A., Su, X., Siefker-Radtke, A., Dinney, C., & McConkey, D. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.129 · Cited by 302
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
Bashashati, A., Haffari, G., Ding, J., Ha, G., Lui, K., Rosner, J., Huntsman, D. G., Caldas, C., Aparicio, S. A., & Shah, S. P. (2012) · Genome Biology · doi:10.1186/gb-2012-13-12-r124 · Cited by 302
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data
Zhang, X., Lu, X., Shi, Q., Xu, X.-Q., Leung, H.-C. E., Harris, L. N., Iglehart, J. D., Miron, A., Liu, J. S., & Wong, W. H. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-197 · Cited by 300
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Robinson, J. L. L., MacArthur, S., Ross‐Innes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., & Carroll, J. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.216 · Cited by 300
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
Sneddon, J. B., Zhen, H. H., Montgomery, K., van de Rijn, M., Tward, A. D., West, R., Gladstone, H., Chang, H. Y., Morganroth, G. S., Oro, A. E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606857103 · Cited by 299
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J. (2021) · Cancers · doi:10.3390/cancers13174455 · Cited by 298
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedPatterns and functional implications of rare germline variants across 12 cancer types
Lu, C., Xie, M., Wendl, M. C., Wang, J., McLellan, M. D., Leiserson, M. D. M., Huang, K.-L., Wyczalkowski, M. A., Jayasinghe, R., Banerjee, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms10086 · Cited by 296
Wnt signaling in triple-negative breast cancer
Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 296
Statistical and integrative system-level analysis of DNA methylation data
Teschendorff, A. E., & Relton, C. L. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.86 · Cited by 296
Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
Lee, J. S., Adler, L., Karathia, H., Carmel, N., Rabinovich, S., Auslander, N., Keshet, R., Stettner, N., Silberman, A., Agemy, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.019 · Cited by 296
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andreetta, C., Mansutti, M., Pisa, F. E., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0002 · Cited by 295
Practical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes
Heo, Y. J., Hwa, C., Lee, G.-H., Park, J.-M., & An, J.-Y. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0042 · Cited by 294
Budoff, M. J., Mayrhofer, T., Ferencik, M., Bittner, D., Lee, K. L., Lu, M. T., Coles, A., Jang, J., Krishnam, M., Douglas, P. S., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030578 · Cited by 293
Liu, B. Y., McDermott, S. P., Khwaja, S. S., & Alexander, C. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400699101 · Cited by 293
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen-Dale, A.-L., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291
Targeting AKT for cancer therapy
Shariati, M., & Meric-Bernstam, F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1676726 · Cited by 290
Transcriptome Profiling in Human Diseases: New Advances and Perspectives
Casamassimi, A., Federico, A., Rienzo, M., Esposito, S., & Ciccodicola, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081652 · Cited by 289
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
Genomewide view of gene silencing by small interfering RNAs
Chi, J.-T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., & Brown, P. O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1037853100 · Cited by 285
Spooner, A., Chen, E., Sowmya, A., Sachdev, P., Kochan, N. A., Trollor, J., & Brodaty, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-77220-w · Cited by 284
Huo, D., Hu, H., Rhie, S. K., Gamazon, E. R., Cherniack, A. D., Liu, J., Yoshimatsu, T. F., Pitt, J. J., Hoadley, K. A., Troester, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0595 · Cited by 283
Logue, S. E., McGrath, E. P., Cleary, P., Greene, S., Mnich, K., Almanza, A., Chevet, E., Dwyer, R. M., Oommen, A., Legembre, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05763-8 · Cited by 283
Gusterson, B. A., Ross, D. T., Heath, V. J., & Stein, T. (2005) · Breast Cancer Research · doi:10.1186/bcr1041 · Cited by 282
Patient-derived xenograft models of breast cancer and their predictive power
Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0523-1 · Cited by 282
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Krenn-Pilko, S., Langsenlehner, U., Thurner, E.-M., Stojakovic, T., Pichler, M., Gerger, A., Kapp, K. S., & Langsenlehner, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.163 · Cited by 281
Myoepithelial Cells: Their Origin and Function in Breast Morphogenesis and Neoplasia
Gudjonsson, T., Adriance, M. C., Sternlicht, M. D., Petersen, O. W., & Bissell, M. J. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-9586-4 · Cited by 281
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 281
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
Ricoult, S. J. H., Yecies, J. L., Ben-Sahra, I., & Manning, B. D. (2016) · Oncogene · doi:10.1038/onc.2015.179 · Cited by 281
circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis
Xu, J.-Z., Shao, C.-C., Wang, X.-J., Zhao, X., Chen, J.-Q., Ouyang, Y.-X., Feng, J., Zhang, F., Huang, W.-H., Ying, Q., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1382-y · Cited by 281
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1349 · Cited by 280
Deep learning-based survival prediction for multiple cancer types using histopathology images
Wulczyn, E., Steiner, D. F., Xu, Z., Sadhwani, A., Wang, H., Flament-Auvigne, I., Mermel, C. H., Chen, P.-H. C., Liu, Y., & Stumpe, M. C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233678 · Cited by 266
Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 279
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26502-6 · Cited by 279
EGFR associated expression profiles vary with breast tumor subtype
Hoadley, K. A., Weigman, V. J., Fan, C., Sawyer, L. R., He, X., Troester, M. A., Sartor, C. I., Rieger-House, T., Bernard, P. S., Carey, L. A., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-258 · Cited by 278
A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes
Debray, T. P., Damen, J. A., Riley, R. D., Snell, K., Reitsma, J. B., Hooft, L., Collins, G. S., & Moons, K. G. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280218785504 · Cited by 278
McConkey, D. J., Choi, W., Shen, Y., Lee, I.-L., Porten, S., Matin, S. F., Kamat, A. M., Corn, P., Millikan, R. E., Dinney, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.034 · Cited by 277
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Precision oncology for acute myeloid leukemia using a knowledge bank approach
Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., Heuser, M., Thol, F., Bolli, N., Ganly, P., et al. (2017) · Nature Genetics · doi:10.1038/ng.3756 · Cited by 276
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Schoch, C., Kohlmann, A., Schnittger, S., Brors, B., Dugas, M., Mergenthaler, S., Kern, W., Hiddemann, W., Eils, R., & Haferlach, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142103599 · Cited by 274
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
Breast tumor microenvironment structures are associated with genomic features and clinical outcome
Danenberg, E., Bardwell, H., Zanotelli, V. R. T., Provenzano, E., Chin, S.-F., Rueda, O. M., Green, A., Rakha, E., Aparicio, S., Ellis, I. O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01041-y · Cited by 274
Translational AI and deep learning in diagnostic pathology
Serag, A., Ion-Margineanu, A., Qureshi, H., McMillan, R., Saint Martin, M.-J., Diamond, J., O'Reilly, P., & Hamilton, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00185 · Cited by 274
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium
Blankenberg, S., Salomaa, V., Makarova, N., Ojeda, F., Wild, P., Lackner, K. J., Jørgensen, T., Thorand, B., Peters, A., Nauck, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw172 · Cited by 273
B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
Moyano, J. V. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25888 · Cited by 272
The WISDOM Study: breaking the deadlock in the breast cancer screening debate
Esserman, L. J., the WISDOM Study and Athena Investigators, Anton-Culver, H., Borowsky, A., Brain, S., Cink, T., Crawford, B., Eklund, M., Esserman, L., Fenton, J., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0035-5 · Cited by 272
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment
Yeboah, J., Young, R., McClelland, R. L., Delaney, J. C., Polonsky, T. S., Dawood, F. Z., Blaha, M. J., Miedema, M. D., Sibley, C. T., Carr, J. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.058 · Cited by 270
Body Mass Index, the Most Widely Used But Also Widely Criticized Index
Ortega, F. B., Sui, X., Lavie, C. J., & Blair, S. N. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.01.008 · Cited by 270
Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
Martinelli, P., Carrillo-de Santa Pau, E., Cox, T., Sainz, B., Dusetti, N., Greenhalf, W., Rinaldi, L., Costello, E., Ghaneh, P., Malats, N., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311256 · Cited by 269
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
TPMCalculator: one-step software to quantify mRNA abundance of genomic features
Vera Alvarez, R., Pongor, L. S., Mariño-Ramírez, L., & Landsman, D. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty896 · Cited by 268
Soundararajan, P., & Kim, J. S. (2018) · Molecules · doi:10.3390/molecules23112983 · Cited by 268
Sebestyén, E., Singh, B., Miñana, B., Pagès, A., Mateo, F., Pujana, M. A., Valcárcel, J., & Eyras, E. (2016) · Genome Research · doi:10.1101/gr.199935.115 · Cited by 276
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S. D., Alferez, D. G., Aparicio, S., Behbod, F., Bentires-Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 267
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13112824 · Cited by 267
Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas
Rosario, S. R., Long, M. D., Affronti, H. C., Rowsam, A. M., Eng, K. H., & Smiraglia, D. J. (2018) · Nature Communications · doi:10.1038/s41467-018-07232-8 · Cited by 266
Biomarker Identification by Feature Wrappers
Xiong, M., Fang, X., & Zhao, J. (2001) · Genome Research · doi:10.1101/gr.190001 · Cited by 266
How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M., & Sherman, M. E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju165 · Cited by 265
Toska, E., Osmanbeyoglu, H. U., Castel, P., Chan, C., Hendrickson, R. C., Elkabets, M., Dickler, M. N., Scaltriti, M., Leslie, C. S., Armstrong, S. A., et al. (2017) · Science · doi:10.1126/science.aah6893 · Cited by 265
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 265
The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy
Wang, J., Xie, S., Yang, J., Xiong, H., Jia, Y., Zhou, Y., Chen, Y., Ying, X., Chen, C., Ye, C., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0747-0 · Cited by 264
Pioneer factors in hormone-dependent cancers
Jozwik, K. M., & Carroll, J. S. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3263 · Cited by 264
Cook, N. R., Paynter, N. P., Eaton, C. B., Manson, J. E., Martin, L. W., Robinson, J. G., Rossouw, J. E., Wassertheil-Smoller, S., & Ridker, P. M. (2012) · Circulation · doi:10.1161/circulationaha.111.075929 · Cited by 263
Shames, D. S., Girard, L., Gao, B., Sato, M., Lewis, C. M., Shivapurkar, N., Jiang, A., Perou, C. M., Kim, Y. H., Pollack, J. R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030486 · Cited by 262
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Calza, S., Hall, P., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., Liu, E. T., Miller, L., Ploner, A., Smeds, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1517 · Cited by 262
Myoepithelial cells: good fences make good neighbors
Adriance, M. C., Inman, J. L., Petersen, O. W., & Bissell, M. J. (2005) · Breast Cancer Research · doi:10.1186/bcr1286 · Cited by 262
Barzegar, N., Tohidi, M., Hasheminia, M., Azizi, F., & Hadaegh, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01121-5 · Cited by 261
Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01556-2 · Cited by 261
The cancer genome atlas pan-cancer analysis project
Mills, G. B., Mills Shaw, K. R., Shmulevich, I., Stuart, J. M., Ellrott, K., Sander, C., The Cancer Genome Atlas Research Network, Collisson, E. A., Ozenberger, B. A., & Weinstein, J. N. (2019) · PubMed · doi:10.17615/670y-yr53 · Cited by 261
Gene Expression Patterns in Renal Cell Carcinoma Assessed by Complementary DNA Microarray
Higgins, J. P. T., Shinghal, R., Gill, H., Reese, J. H., Terris, M., Cohen, R. J., Fero, M., Pollack, J. R., van de Rijn, M., & Brooks, J. D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63887-4 · Cited by 260
Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C
Dryden, N. H., Broome, L. R., Dudbridge, F., Johnson, N., Orr, N., Schoenfelder, S., Nagano, T., Andrews, S., Wingett, S., Kozarewa, I., et al. (2014) · Genome Research · doi:10.1101/gr.175034.114 · Cited by 260
Ishwaran, H., & Lu, M. (2019) · Statistics in Medicine · doi:10.1002/sim.7803 · Cited by 260
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Taftaf, R., Liu, X., Singh, S., Jia, Y., Dashzeveg, N. K., Hoffmann, A. D., El-Shennawy, L., Ramos, E. K., Adorno-Cruz, V., Schuster, E. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25189-z · Cited by 261
Meyer, M., Ronald, J., Vernuccio, F., Nelson, R. C., Ramirez-Giraldo, J. C., Solomon, J., Patel, B. N., Samei, E., & Marin, D. (2019) · Radiology · doi:10.1148/radiol.2019190928 · Cited by 258
The mitochondrial calcium uniporter regulates breast cancer progression via HIF ‐1α
Tosatto, A., Sommaggio, R., Kummerow, C., Bentham, R. B., Blacker, T. S., Berecz, T., Duchen, M. R., Rosato, A., Bogeski, I., Szabadkai, G., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606255 · Cited by 258
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Signoretti, S., Marcotullio, L. D., Richardson, A. L., Ramaswamy, S., Isaac, B. M., Rué, M., Monti, F., Loda, M. F., & Pagano, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15795 · Cited by 257
Retracted
Metadata
- Authors
- Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 85
- Issue
- 2
- Pages
- 100-110
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2044702943
- Cited by
- 13,166
- References
- 236
- FWCI
- 323.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.